A Critical Risk-Benefit Assessment Argues Against the Use of Anthracyclines in Induction Regimens for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia

References

• Gurney J G, Severson R K, Davis S, Robison L L. Incidence of cancer in children in the United States. Sex‐, race‐, and 1‐year age‐specific rates by histologic type. Cancer 1995; 75: 2186–95
   PubMed Web of Science ®Google Scholar
• Elphinstone T. International Register of Current Randomized Trials in Childhood Acute Lymphoblastic Leukemia. Chidhood ALL Collaborative Group Secretariat, Clinical Trial Service Unit, OxfordUK 1997
   Google Scholar
• Reiter A, Schrappe M, Ludwig W D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL‐BFM 86. Blood 1994; 84: 3122–33
   PubMed Web of Science ®Google Scholar
• Tubergen D O, Gilchrist G S, O'Brien R T, Coccia P F, Sather H N, Waskerwitz M J, Hammond G D. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 1993; 11: 527–37
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, Carroll A J, Crist W, Gaynon P, Gelber R, Heerema N, Korn E L, Link M, Murphy S, Pui C H, Pullen J, Reamon G, Sallan S E, Sather H, Shuster J, Simon R, Trigg M, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Gottlieb A J, Weinberg V, Ellison R R, Henderson E S, Tere‐belo H, Rafla S, Cuttner J, Silver R T, Carey R W, Levy R N, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood 1984; 64: 267–74
   PubMed Web of Science ®Google Scholar
• Holland J F. E Pluribus Unum: Presidential address. Cancer Res 1971; 31: 1319–29
   PubMed Web of Science ®Google Scholar
• Hitchcock Bryan S, Gelber R, Cassady J R, Sallan S E. The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14: 211–5
   PubMedGoogle Scholar
• Sallan S E, Camitta B M, Frei Ed, Furman L, Leavitt P, Bishop Y, Jaffe N. Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone. Med Pediatr Oncol 1977; 3: 281–7
   PubMedGoogle Scholar
• van der Does van den Berg A, van Wering E R, Suciu S, Solbu G, van't Veer M B, Rammeloo J A, de Koning J, van Zanen G E. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). Am J Pediatr Hematol Oncol 1989; 11: 125–33
   PubMedGoogle Scholar
• Verzosa M, Fite A. Efficacy and morbidity of daunomy‐cin (NSC‐82151) added to vincristine (NSC‐67574) and prednisone (NSC‐10023) for remission induction of childhood acute lymphocytic leukemia. Cancer Chemother Rep 1971; 55: 79–82
   PubMedGoogle Scholar
• Eden O B, Lilleyman J S, Richards S, Shaw M P, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol 1991; 78: 187–96
   PubMed Web of Science ®Google Scholar
• Treatment of childhood acute lymphoblastic leukemia: randomized trials of protocols CCLSG‐L 841 and I 841. (Phase III study). Children's Cancer and Leukemia Study Group. Rinsho Ketsueki 1989; 30: 967–74
   PubMedGoogle Scholar
• Lilleyman J S, Gibson B E, Stevens R F, Will A M, Hann I M, Richards S M, Hill F G. Clearance of marrow infiltration after I week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1997; 97: 603–6
   PubMed Web of Science ®Google Scholar
• Gaynon P S, Desai A A, Bostrom B C, Hutchinson R J, Lange B J, Nachman J B, Reaman G H, Sather H N, Steinherz P G, Trigg M E, Tubergen D G, Uckun F M. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717–26
   PubMed Web of Science ®Google Scholar
• Humphrey G B, Fembach D J, Razek A A, Stuckey W J, George S. Evaluation of daunorubicin (NSC‐82151) and methotrexate (NSC‐740) in combination as a remission maintenance regimen in the treatment of acute leukemia. Cancer Chemotherapy Reports 1975; 59: 395–399
   PubMedGoogle Scholar
• Culbert S J, Shuster J J, Land V J, Wharam M D, Thomas P R, Nitschke R, Pinkel D, Vietti T J. Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study. Cancer 1991; 67: 37–42
   PubMed Web of Science ®Google Scholar
• Ek O, Gaynon P, Zeren T, Chelstrom L, Myers D E, Uckun F M. Treatment of human B‐cell precursor leukemia in SCID mice using combination of the Anti‐CD 19 irnmuno‐toxin B43‐PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone and L‐Asparaginase. Leukemia Lymphoma 1998, in press
   Web of Science ®Google Scholar
• Pieters R, Huismans D R, Loonen A H, Hahlen K, Veerman A J. Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6‐hioguanine upon cells from lymphoblastic leukemic patients. Jpn J Cancer Res 1991; 82: 1051–5
   PubMedGoogle Scholar
• Pieters R, Kaspers G J, van Wering E R, Huismans D R, Loonen A H, Hahlen K, Veerman M. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392–7
   PubMed Web of Science ®Google Scholar
• Pieters R, Klumper E, Kaspers G J, Veerman A J. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 1997; 25: 11–26
   PubMed Web of Science ®Google Scholar
• Kaspers G J, Pieters R, Van Zantwijk C H, Van Wering E R, Veerman A J. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 1995; 19: 407–16
   PubMed Web of Science ®Google Scholar
• Klumper E, Pieters R, Veerman A J, Huismans D R, Loonen A H, Hahlen K, Kaspers G J, van Wering E R, Hartmann R, Henze G. In vitro cellular drug resistance in children with relapsedlrefractory acute lymphoblastic leukemia. Blood 1995; 86: 3861–8
   PubMed Web of Science ®Google Scholar
• Goasguen J E, Dossot J M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise P Y, Chaperon J, Fauchet R. Expression of the multidrug resistance‐associated P‐glycoprotein (P‐170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–8
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Zintl F, Volm M. P‐glycoprotein and glu‐tathione S‐transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994; 70: 1144–9
   PubMed Web of Science ®Google Scholar
• Kingreen D, Sperling C, Notter M, et al. Sequential analysis of P‐glycoprotein expression in childhood acute lymphoblastic leukemia. Haematol Blood Transf 1992; 34: 23–28
   Google Scholar
• Ivy S P, Sather H N, Hammond G D, Reaman G H. The prognostic significance of MDRl gene expression at diagnosis in childhood acute lymphoblastic leukemia. Pediatric Res 1993; 33: 141A
   Google Scholar
• Kanerva J, Tiirikainen M, Makipemaa A, Riikonen P, Mot‐tonen M, Salmi T T, Krusius T, Saarinen‐Pihkala U M. Multiple drug resistance mediated by P‐glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998; 15: 11–21
   PubMed Web of Science ®Google Scholar
• Pieters R, Hongo T, Loonen A H, Huismans D R, Broxter‐man W, Hahlen K, Veerman A J. Different types of non‐P‐glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer 1992; 65: 691–7
   PubMed Web of Science ®Google Scholar
• Ivy S P, Smith J K, Speciale A, Sather H N, Hammond G D, Reaman G H. Detection of mdrl gene expression using polymerase chain reaction (PCR) in childhood acute lymphoblastic leukemia (ALL) at diagnosis. Proc Am Ass Cancer Res 1992; 33: 473A
   Google Scholar
• Beck J, Handgretinger R, Dopfer R, Klingebiel T, Nietham‐mer D, Gekeler V. Expression of mdrl, mrp, topoisomerase II alphaeta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995; 89: 356–63
   PubMed Web of Science ®Google Scholar
• Gekeler V, Frese G, Noller A, Handgretinger R, Wilisch A, Schmidt H, Muller C P, Dopfer R, Klingebiel T, Diddens H, et al. MdrVP‐glycoprotein, topoisomerase, and glu‐tathione‐S‐transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 1992; 66: 507–17
   PubMed Web of Science ®Google Scholar
• Hegewisch Becker S, Faltz C, Hossfeld D K. Prolongation of medium exchange is associated with a decrease in function but not expression of the P‐glycoprotein pump in leu‐kaemic cells. Eur J Haematol 1996; 56: 12–22
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Michelutti A, Candoni A, Maso‐lini P, Scaggiante B, Quadrifoglio F, Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170‐elated multidrug resistance cells by low concentration D‐verapamil, cyclosporin‐A and SDZ PSC 833. Hae‐matologica 1994; 79: 500–7
   PubMed Web of Science ®Google Scholar
• Damiani D, Michieli M, Michelutti A, Melli C, Cerno M, Baccarani M. D‐verapamil downmodulates P170‐ssoci‐ated resistance to doxorubicin, daunorubicin and idarubicin. Anticancer Drugs 1993; 4: 173–80
   PubMed Web of Science ®Google Scholar
• Osann K, Sweet P, Slater L M. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug‐resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 1992; 30: 152–4
   PubMed Web of Science ®Google Scholar
• Solary E, Bidan J M, Calvo F, Chauffert B, Caillot D, Mug‐neret F, Gauville C, Tsuruo T, Carli P M, Guy H. P‐glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 1991; 5: 592–7
   PubMed Web of Science ®Google Scholar
• Slater L M, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986; 77: 1405–8
   PubMed Web of Science ®Google Scholar
• Cowie F J, Pinkerton C R, Phillips M, Dick G, Judson I, McCarthy P T, Flanagan R J. Continuous‐infusion verapamil with etoposide in relapsed or resistant paediatric cancers. BrJ Cancer 1995; 71: 877–81
   PubMed Web of Science ®Google Scholar
• Beksac M, Akan H, Koc H, Ilhan O, Erturk S, Guneyli A, Ikizunal Y, Sardas O S. P‐glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols. Med Oncol Tumor Pharrnacother 1992; 9: 101–5
   PubMed Web of Science ®Google Scholar
• Miniero R, Massara F M, Saroglia E M, Soldano S, Barisone E, Leone L, Arrighini A, Andolina M, Brach del Prever A, Madon E. Use of cyclosporin and verapamil in association with chemotherapy in the treatment of pediatric patients with advanced‐stage neoplasms. A pilot study. Minerva Pediatr 1994; 46: 463–70
   PubMedGoogle Scholar
• Cole S P, Bhardwaj G, Gerlach J H, Mackie J E, Grant C E, Almquist K C, Stewart A J, Kurz E U, Duncan A M, Deeley R G. Overexpression of a transporter gene in a multi‐drug‐resistant human lung cancer cell line. Science 1992; 258: 1650–4
   PubMed Web of Science ®Google Scholar
• Grant C E, Valdimarsson G, Hipfner D R, Almquist K C, Cole S P, Deeley R G. Overexpression of multidrug resistance‐associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357–61
   PubMed Web of Science ®Google Scholar
• Krishnamachary N, Ma L, Zheng L, Safa A R, Center M S. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res 1994; 6: 119–27
   PubMed Web of Science ®Google Scholar
• Scheper R J, Broxterman H J, Scheffer G L, Kaaijk P, Dalton W S, van Heijningen T H, van Kalken C K, Slovak M L, de Vries E G, van der Valk P, et al. Overexpression of a M(r) 110,000 vesicular protein in non‐P‐ glycoprotein‐mediated multidrug resistance. Cancer Res 1993; 53: 1475–9
   PubMed Web of Science ®Google Scholar
• Zaman G J, Versantvoort C H, Smit J J, Eijdems E W, de Haas M, Smith A J, Broxterman H J, Mulder N H, de Vries E G, Baas F, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993; 53: 1747–50
   PubMed Web of Science ®Google Scholar
• den Boer M L, Pieters R, Kazemier K M, Rottier M M, Zwaan C M, Kaspers G J, Janka‐Schaub G, Henze G, Creutzig U, Scheper R J, Veerman A J. Relationship between major vault proteinflung resistance protein, multi‐drug resistance‐associated protein, P‐glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092–8
   PubMed Web of Science ®Google Scholar
• Maung Z T, Hogarth L, Reid M M, Proctor S J, Hamilton P J, Hall A G. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia. Leukemia 1994; 8: 1487–91
   PubMed Web of Science ®Google Scholar
• Hall A G, Autzen P, Cattan A R, Malcolm A J, Cole M, Ker‐nahan J, Reid M M. Expression of mu class glutathione S‐transferase correlates with event‐free survival in childhood acute lymphoblastic leukemia. Cancer Res 1994; 54: 5251–4
   PubMed Web of Science ®Google Scholar
• Van Luyn M J, Muller M, Renes J, Meijer C, Scheper R J, Nienhuis E F, Mulder N H, Jansen P L, De Vries E G. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug‐resistance protein 1. Int J Cancer 1998; 76: 55–62
   PubMed Web of Science ®Google Scholar
• Versantvoort C H, Broxterman H J, Bagrij T, Scheper R J, Twentyman P R. Regulation by glutathione of drug transport in multidrug‐resistant human lung tumour cell lines overexpressing multidrug resistance‐ associated protein. Br J Cancer 1995; 72: 82–9
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP‐dependent transport of glutathione S‐conjugates by the multidrug resistance‐associated protein. Cancer Res 1994; 54: 4833–6
   PubMed Web of Science ®Google Scholar
• Wang J C. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635–92
   PubMed Web of Science ®Google Scholar
• Watt P M, Hickson I D. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681–95
   PubMed Web of Science ®Google Scholar
• Chen A Y, Liu A F. Mechanisms of resistance to topoi‐somerase in hibitors. Anticancer Drug Resistance: Advances in Molecular and Clinical Research, L J Goldstein, R F Ozols. Kluwer Academic Publishers, Boston 1994; 263
   Google Scholar
• Pommier Y, Leteurtre F, Fesen M R, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn K W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530–42
   PubMed Web of Science ®Google Scholar
• Liu L F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Yamada K, Egashira M, Yazaki Y, Hirai H, Kikuchi A, Oshimi K. Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL‐60 cells. Blood 1998; 91: 1407–1417
   PubMed Web of Science ®Google Scholar
• Brown G A, McPherson J P, Gu L, Hedley D W, Toso R, Deuchars K L, Freedman M H, Goldenberg G J. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 1995; 55: 78–82
   PubMed Web of Science ®Google Scholar
• Klumper E, Giaccone G, Pieters R, Broekema G, van Ark Otte J, van Wering E R, Kaspers G J, Veerman A J. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1653–60
   PubMed Web of Science ®Google Scholar
• Fink D, Aebi S, Howell S B. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1–6
   PubMed Web of Science ®Google Scholar
• Fink D, Nebel S, Noms P S, Aebi S, Kim H K, Haas M, Howell S B. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair‐deficient tumour cells. Br J Cancer 1998; 77: 703–8
   PubMed Web of Science ®Google Scholar
• Bleyer W A. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990; 40: 355–67
   PubMed Web of Science ®Google Scholar
• Cathbertson D D, Epstein S T, Lipshultz S E, et al. Anthracy‐cline cardiotoxicity in children with cancer. [Abstract]. Circulation 1994; 90: 150
   Google Scholar
• Shan K, Lincoff A M, Young J B. Anthracycline‐induced cardiotoxicity. Ann Intem Med 1996; 125: 47–58
   PubMed Web of Science ®Google Scholar
• Von Hoff D D, Rozencweig M, Layard M, Slavik M, Mug‐gia F M. Daunomycin‐induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200–8
   PubMed Web of Science ®Google Scholar
• Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin‐induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775–82
   PubMed Web of Science ®Google Scholar
• Dorr R T. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23: 23–34
   PubMed Web of Science ®Google Scholar
• Bristow M R, Kantrowitz N E, Harrison W D, Minobe W A, Sageman W S, Billingham M E. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 1983; 5: 913–9
   PubMed Web of Science ®Google Scholar
• Shan K, Lincoff A M. Anthracycline‐Induced Cardiotoxicity [Letter]. Annals of Internal Medicine 1997; 126: 827–828
   Web of Science ®Google Scholar
• Bu'Lock F A, Mott M G, Oakhill A, Martin R P. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73: 340–50
   PubMedGoogle Scholar
• Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M, Gilday D, Smallhom J, Benson L. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 1994; 74: 1152–6
   PubMed Web of Science ®Google Scholar
• Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15: 61–8
   PubMed Web of Science ®Google Scholar
• Lipshultz S E, Lipsitz S R, Mone S M, Sallan S E, Colan S D. Left ventricular structure and function eleven years after doxorubicin treatment for childhood leukemia: is this a restrictive cardiomyopathy process? [Abstract]. J Am Coll Cardiol 1995; 25: 54A
   PubMed Web of Science ®Google Scholar
• Lipshultz S E. Dexrazoxane for protection against car‐diotoxic effects of anthracyclines in children. J Clin Oncol 1996; 14: 328–31
   PubMed Web of Science ®Google Scholar
• Lipshultz S E, Colan S D, Gelber R D, Perez Atayde A R, Sallan S E, Sanders S P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–15
   PubMed Web of Science ®Google Scholar
• Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, Keck E W. Long term doxorubicin cardiotox‐icity in childhood non‐invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988; 60: 309–15
   PubMedGoogle Scholar
• Sorensen K, Levitt G, Sebag Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995; 13: 1546–56
   PubMed Web of Science ®Google Scholar
• Steinherz L J, Steinherz P G, Tan C T, Heller G, Murphy M L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–7
   PubMed Web of Science ®Google Scholar
• Von Hoff D D, Layard M W, Basa P, Davis H L, Jr., Von Hoff A L, Rozencweig M, Muggia F M. Risk factors for doxoru‐bicin‐induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
   PubMed Web of Science ®Google Scholar
• Steinherz L J, Steinherz P G, Tan C. Cardiac failure and dys‐rhyhmas 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24: 352–61
   PubMedGoogle Scholar
• Steinherz L J. Anthracycline‐Induced Cardiotoxicity [Letter]. Annals of Internal Medicine 1997; 126: 827
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S L, Blumenschein G R, Freireich E J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9
   PubMed Web of Science ®Google Scholar
• Steinherz P G, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan‐Kettering‐New York‐II protocol. Cancer 1993; 72: 3120–30
   PubMed Web of Science ®Google Scholar
• Bielack S S, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti‐tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873–82
   PubMedGoogle Scholar
• Abraham R, Basser R L, Green M D. A risk‐benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Saf 1996; 15: 406–29
   PubMed Web of Science ®Google Scholar
• Gabizon A A. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994; 8: 431–50
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54(Suppl 4)1–7
   PubMed Web of Science ®Google Scholar
• Alberts D S, Garcia D J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(Suppl 4)30–5
   PubMed Web of Science ®Google Scholar
• Hasinoff B B. The interaction of the cardioprotective agent ICRF‐187 [+)‐1, 2‐is(3, 5‐ioxopiperazinyl‐1‐L)pro‐pane); its hydrolysis product (ICRF‐198); and other chelat‐ing agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989; 26: 378–85
   PubMedGoogle Scholar
• Hellmann K. Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier–harpens antitu‐mor profile and therapeutic index [editorial]. J Clin Oncol 1996; 14: 332–3
   PubMed Web of Science ®Google Scholar
• Wexler L H, Andrich M P, Venzon D, Berg S L, Weaver McClure L, Chen C C, Dilsizian V, Avila N, Jarosinski P, Balk F M, Poplack D G, Horowitz M E. Randomized trial of the cardioprotective agent ICRF‐187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362–72
   PubMed Web of Science ®Google Scholar
• Shaddy R E, Olsen S L, Bristow M R, Taylor D O, Bullock E A, Tani L Y, Renlund D G. Efficacy and safety of meto‐prolol in the treatment of doxorubicin‐ induced cardiomyopathy in pediatric patients. Am Heart J 1995; 129: 197–9
   PubMed Web of Science ®Google Scholar
• Lipshultz S E, Lipsitz S R, Sallan S E, Gelber R D, Cohen S D. Is enalapril beneficial in doxorubicin‐treated long‐term survivors of childhood cancer?. Circulation 1997; 96: 1–436, Abs 2438
   Web of Science ®Google Scholar
• Marquardt H, Philips F S, Sternberg S S. Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomy‐cin. Cancer Res 1976; 36: 2065–9
   PubMed Web of Science ®Google Scholar
• Anderson R D, Berger N A. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoi‐somerase‐interactive agents. Mutat Res 1994; 309: 109–42
   PubMed Web of Science ®Google Scholar
• Pedersen Bjergaard J, Rowley J D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–6
   PubMed Web of Science ®Google Scholar
• Pedersen Bjergaard J, Philip P. Balanced translocations involving chromosome bands llq23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA‐topoi‐somerase II [letter]. Blood 1991; 78: 1147–8
   PubMed Web of Science ®Google Scholar
• Pui C H, Behm F G, Raimondi S C, Dodge R K, George S L, Rivera G K, Mirro J, Jr, Kalwinsky D K, Dahl G V, Murphy S B. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136–42
   PubMed Web of Science ®Google Scholar
• Ratain M J, Kaminer L S, Bitran J D, Larson R A, Le Beau M M, Skosey C, Purl S, Hoffman P C, Wade J, Vardi‐man J W, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non‐small‐cell carcinoma of the lung. Blood 1987; 70: 1412–7
   PubMed Web of Science ®Google Scholar
• Sandoval C, Pui C H, Bowman L C, Heaton D, Hurwitz C A, Raimondi S C, Behm F G, Head D R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; II: 1039–45
   Google Scholar
• Bjergaard Pedersen J, Daugaard G, Hansen S W, Philip P, Larsen S O, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ‐cell tumours. Lancet 1991; 338: 359–63
   PubMed Web of Science ®Google Scholar
• Quesnel B, Kantarjian H, Bjergaard J P, Brault P, Estey E, Lai J L, Tilly H, Stoppa A M, Archimbaud E, Harousseau J L, et al. Therapy‐related acute myeloid leukemia with t(8;21), inv(16). and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370–9
   PubMed Web of Science ®Google Scholar
• Detourmignies L, Castaigne S, Stoppa A M, Harousseau J L, Sadoun A, Janvier M, Demory J L, Sanz M, Berger R, Bau‐ters F, et al. Therapy‐related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992; 10: 1430–5
   PubMed Web of Science ®Google Scholar
• Thirman M J, Gill H J, Burnett R C, Mbangkollo D, McCabe N R, Kobayashi H, Ziemin van der Poel S, Kaneko Y, Morgan R, Sandberg A A, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with llq23 chromosomal translocations. N Engl J Med 1993; 329: 909–14
   PubMed Web of Science ®Google Scholar
• Bjergaard Pedersen J. Acute lymphoid leukemia with t(4;ll) (q21;q23) following chemotherapy with cytostatic agents targeting at DNA‐topoisomerase II [editorial]. Leuk Res 1992; 16: 733–5
   PubMed Web of Science ®Google Scholar
• Bjergaard Pedersen J, Nielsen Brondum K, Karle H, Johansson B. Chemotherapy‐related ‐ late occurring ‐Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?. Leukemia 1997; 11: 1571–4
   PubMed Web of Science ®Google Scholar
• Johansson B, Mertens F, Heim S, Kristoffersson U, Mitel‐man F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Hae‐matol 1991; 47: 17–27
   PubMed Web of Science ®Google Scholar
• Le Beau M M, Albain K S, Larson R A, Vardiman J W, Davis E M, Blough R R, Golomb H M, Rowley J D. Clinical and cytogenetic correlations in 63 patients with therapy‐ related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4: 325–45
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Walters R S, Smith T L, Cork A, McCredie K B, Freireich E J. Therapy‐related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748–57
   PubMed Web of Science ®Google Scholar
• Pedersen Bjergaard J, Philip P, Larsen S O, Jensen G, Byrst‐ing K. Chromosome aberrations and prognostic factors in therapy‐related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083–91
   PubMed Web of Science ®Google Scholar
• Pui C H, Ribeiro R C, Hancock M L, Rivera G K, Evans W E, Raimondi S C, Head D R, Behm F G, Mahmoud M H, Sand‐lund J T, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682–7
   PubMed Web of Science ®Google Scholar
• Pui C H, Relling M V, Rivera G K, Hancock M L, Raimondi S C, Heslop H E, Santana V M, Ribeiro R C, Sandlund J T, Mahmoud H H, et al. Epipodophyllotoxin‐related acute myeloid Ieukemia: a study of 35 cases. Leukemia 1995; 9: 1990–6
   PubMed Web of Science ®Google Scholar
• Winick N J, McKenna R W, Shuster J J, Schneider N R, Borowitz M J, Bowman W P, Jacaruso D, Kamen B A, Buchanan G R. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etopo‐side. J Clin Oncol 1993; 11: 209–17
   PubMed Web of Science ®Google Scholar
• Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, Ohira M, Nishimura K. High frequency of eto‐poside (VP‐16)dated secondary leukemia in children with non‐Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1993; 15: 99–104
   PubMedGoogle Scholar
• Neglia J P, Meadows A T, Robison L L, Kim T H, Newton W A, Ruymann F B, Sather H N, Hammond G D. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330–6
   PubMed Web of Science ®Google Scholar
• Tucker M A, Meadows A T, Boice J D, Jr, Stovall M, Ober‐lin O, Stone B J, Birch J, Voute P A, Hoover R N, Fraumeni J F, Jr. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987; 78: 459–64
   PubMed Web of Science ®Google Scholar
• Valagussa P, Bonadonna G. Carcinogenic effects of cancer treatment. Oxford Textbook of Oncology, M Peckham, H Pinedo, U Veronesi. Oxford University Press, Oxford 1995; 2348–2358
   Google Scholar
• Heyn R, Khan F, Ensign L G, Donaldson S S, Ruymann E, Smith M A, Vietti T, Maurer H M. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophos‐phamide and low‐dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 1994; 23: 99–106
   PubMedGoogle Scholar
• Green D M, Zevon M A, Reese P A, Lowrie G S, Gaeta J F, Pearce J I, Michalek A M, Stephens E A. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol 1994; 22: 1–10
   PubMedGoogle Scholar
• Breslow N E, Takashima J R, Whitton J A, Moksness J, D'Angio G J, Green D M. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995; 13: 1851–9
   PubMed Web of Science ®Google Scholar
• Launchbury A P, Habboubi N. Epirubicin and doxorubi‐cin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197–228
   PubMed Web of Science ®Google Scholar